Skip to main content

Advertisement

Log in

No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer

  • Letter to the Editor
  • Published:
World Journal of Urology Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 22 February 2018

The Original Article was published on 21 April 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vargas A, Machado RD, Filho DI, Paiva CE, Dos Reis RB, Tobias-Machado M, Faria EF (2016) LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol 34(12):1621–1628

    Article  CAS  PubMed  Google Scholar 

  2. Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M (2003) Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment. Hinyokika Kiyo 49(9):521–525

    PubMed  Google Scholar 

  3. Ostergren PB, Kistorp C, Fode M, Henderson J, Bennedbaek FN, Faber J, Sonksen J (2016) Luteinizing hormone-releasing hormone agonists are superior to subcapsular orchiectomy in lowering testosterone levels of men with prostate cancer: results from a randomized clinical trial. J Urol. doi:10.1016/j.juro.2016.12.003 (Epub ahead of print)

    PubMed  Google Scholar 

  4. Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van HM (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1243–1251

    Article  PubMed  Google Scholar 

Download references

Author contributions

PBØ: Project development, Data management, Data analysis, Manuscript editing. TWK: Data management, Data analysis, Manuscript editing. MF: Project development, Data management, Data analysis, Manuscript writing.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mikkel Fode.

Ethics declarations

Conflict of interest

This is a letter to the editor not directly involving human participants or animals. The authors would like to declare the following conflicts of interest: Peter B. Østergren has received honorarium as a speaker for Astellas and Ferring. Mikkel Fode has received honorarium as a speaker and advisory board member for Astellas. Tobias Wirenfeldt Klausen has no conflicts of interest.

Additional information

This comment refers to the article available at doi:10.1007/s00345-016-1831-5.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Østergren, P.B., Klausen, T.W. & Fode, M. No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer. World J Urol 36, 681–682 (2018). https://doi.org/10.1007/s00345-017-2012-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-017-2012-x

Keywords

Navigation